Last quarter (Q1 2024), ESSA Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, ESSA Pharma's net income was $-5.96M. See ESSA Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 23	Sep 22	Sep 21	Sep 20	Sep 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 31.87M	$ 32.14M	$ -36.97M	$ 37.17M	$ 23.52M	$ 12.15M
Operating Income	$ -31.86M	$ -32.13M	$ -36.97M	$ -37.17M	$ -23.52M	$ -12.15M
Net Non Operating Interest Income Expense	$ 6.08M	$ 5.55M	$ 1.74M	$ 342.02K	$ -58.39K	$ -576.49K
Other Income Expense	-	-	-	$ -107.02K	$ -155.71K	$ 9.00K
Pretax Income	$ -25.80M	$ -26.58M	$ -35.22M	$ -36.84M	$ -23.73M	$ -12.72M
Tax Provision	$ 1.60K	$ 1.60K	$ -111.82K	$ -34.35K	$ -288.65K	$ 37.92K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -25.80M	$ -26.57M	$ -35.12M	$ -36.81M	$ -23.45M	$ -12.76M
Basic EPS	$ -0.59	$ -0.60	$ -0.80	$ -0.96	$ -1.04	$ -1.24
Diluted EPS	$ -0.59	$ -0.60	$ -0.80	$ -0.96	$ -1.04	$ -1.24
Basic Average Shares	$ 176.41M	$ 44.09M	$ 44.04M	$ 38.48M	$ 22.44M	$ 8.43M
Diluted Average Shares	$ 176.41M	$ 44.09M	$ 44.04M	$ 38.48M	$ 22.44M	$ 8.43M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	$ 59.75K	$ 192.48K
Total Expenses	$ 31.87M	$ 32.14M	$ -36.97M	$ 37.17M	$ 23.52M	$ 12.15M
Net Income From Continuing And Discontinued Operation	$ -25.80M	$ -26.58M	$ -35.12M	$ -36.81M	$ -23.45M	$ -12.76M
Normalized Income	$ -10.23M	$ -21.00M	-	-	$ -23.29M	$ -12.76M
Interest Expense	-	-	-	-	$ 618.11K	$ 602.74K
EBIT	$ -25.80M	$ -26.58M	$ -35.22M	$ -36.84M	$ -23.12M	$ -12.12M
EBITDA	$ -11.61M	$ -27.13M	$ -35.02M	$ -36.73M	$ -23.01M	$ -12.12M

Currency in USD

ESSA Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing